Copyright: ©Author(s) 2026.
World J Gastroenterol. Sep 14, 2026; 32(34): 119567
Published online Sep 14, 2026. doi: 10.3748/wjg.v32.i34.119567
Published online Sep 14, 2026. doi: 10.3748/wjg.v32.i34.119567
Table 7 Multivariate Cox proportional hazards regression analysis of risk factors affecting progression-free survival in gastric cancer patients treated with immune checkpoint inhibitors
| Parameters | P value | Hazard ratio | 95%CI |
| Eastern Cooperative Oncology Group (2) | 0.018 | 1.642 | 1.088-2.478 |
| Clinical staging (IV) | 0.001 | 2.149 | 1.361-3.394 |
| Number of distant metastases (≥ 2) | 0.032 | 1.593 | 1.042-2.435 |
| Treatment regimen (combination therapy) | 0.076 | 0.712 | 0.491-1.032 |
| Programmed cell death ligand 1 overexpression (combined positive score ≥ 1) | 0.124 | 0.803 | 0.608-1.061 |
| High systemic immune-inflammation index (≥ 593.995) | 0.005 | 1.896 | 1.214-2.961 |
- Citation: Guo R, Gao M. Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors. World J Gastroenterol 2026; 32(34): 119567
- URL: https://www.wjgnet.com/1007-9327/full/v32/i34/119567.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i34.119567